IN2012DN01641A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01641A IN2012DN01641A IN1641DEN2012A IN2012DN01641A IN 2012DN01641 A IN2012DN01641 A IN 2012DN01641A IN 1641DEN2012 A IN1641DEN2012 A IN 1641DEN2012A IN 2012DN01641 A IN2012DN01641 A IN 2012DN01641A
- Authority
- IN
- India
- Prior art keywords
- compounds
- pentoxifylline
- derivatives
- relates
- novel
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical class O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 abstract 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960001476 pentoxifylline Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23934209P | 2009-09-02 | 2009-09-02 | |
US12/873,991 US20110053961A1 (en) | 2009-02-27 | 2010-09-01 | Substituted xanthine derivatives |
PCT/US2010/047708 WO2011028922A1 (en) | 2009-09-02 | 2010-09-02 | Substituted xanthine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01641A true IN2012DN01641A (instruction) | 2015-06-05 |
Family
ID=43625765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1641DEN2012 IN2012DN01641A (instruction) | 2009-09-02 | 2010-09-02 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20110053961A1 (instruction) |
EP (2) | EP2963040A1 (instruction) |
JP (1) | JP5292516B2 (instruction) |
KR (1) | KR101591137B1 (instruction) |
CN (2) | CN104478881A (instruction) |
AU (1) | AU2010289465B2 (instruction) |
BR (1) | BR112012008108B1 (instruction) |
CA (1) | CA2771123C (instruction) |
DK (1) | DK2473053T3 (instruction) |
EA (1) | EA023809B1 (instruction) |
ES (1) | ES2542401T3 (instruction) |
HR (1) | HRP20150797T1 (instruction) |
HU (1) | HUE026800T2 (instruction) |
IN (1) | IN2012DN01641A (instruction) |
ME (1) | ME02177B (instruction) |
MX (1) | MX2012002705A (instruction) |
PH (1) | PH12012500278A1 (instruction) |
PL (1) | PL2473053T3 (instruction) |
PT (1) | PT2473053E (instruction) |
SI (1) | SI2473053T1 (instruction) |
WO (1) | WO2011028922A1 (instruction) |
ZA (1) | ZA201201295B (instruction) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0908107A2 (pt) | 2008-02-29 | 2019-09-24 | Concert Pharmaceuticals Inc | composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente |
US20100159034A1 (en) * | 2008-12-15 | 2010-06-24 | Auspex Pharmaceuticals, Inc. | Pyrrolidinone inhibitors of pde-4 |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
US9260432B2 (en) | 2009-09-02 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
AU2010289551A1 (en) * | 2009-09-02 | 2012-03-01 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
EP2611807A2 (en) * | 2010-09-01 | 2013-07-10 | Concert Pharmaceuticals Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione |
US9074233B2 (en) | 2010-09-01 | 2015-07-07 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
US9085788B2 (en) | 2010-09-01 | 2015-07-21 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
KR20150002779A (ko) | 2012-04-13 | 2015-01-07 | 콘서트 파마슈티컬즈, 인크. | 치환된 크산틴 유도체 |
WO2013159006A1 (en) * | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione |
CA2981791A1 (en) * | 2014-04-18 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
WO2015175008A1 (en) * | 2014-05-14 | 2015-11-19 | Concert Pharmaceuticals, Inc. | Methods of treating chronic kidney disease characterized by macroalbuminuria |
WO2015184248A1 (en) * | 2014-05-30 | 2015-12-03 | Concert Pharmaceuticals, Inc. | Methods of treating fibrotic diseases |
CN107001371B (zh) | 2014-10-09 | 2019-07-05 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
CN111233863B (zh) * | 2014-10-09 | 2022-10-25 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
WO2016184312A1 (zh) * | 2015-05-20 | 2016-11-24 | 南京明德新药研发股份有限公司 | 羟基嘌呤类化合物及其应用 |
CN108137592B (zh) * | 2015-11-03 | 2021-03-05 | 纽弗姆制药有限公司 | 用于治疗血癌的氘代化合物以及其组合物和方法 |
CN108699061B (zh) * | 2015-11-16 | 2022-07-05 | 纽弗姆制药有限公司 | 用于治疗血液恶性肿瘤、炎症和自身免疫性疾病的氘代化合物 |
JP2022549807A (ja) * | 2019-09-25 | 2022-11-29 | ゴールドフィンチ バイオ,インク. | キサンチンcb1阻害物質 |
CN111440041B (zh) * | 2020-05-19 | 2021-03-05 | 北京理工大学 | 一种甲苯-d8的合成方法 |
CN114380829A (zh) * | 2021-12-28 | 2022-04-22 | 赤峰万泽药业股份有限公司 | 一种己酮可可碱及其合成方法和应用 |
CN118684672A (zh) * | 2023-03-24 | 2024-09-24 | 陕西麦科奥特科技有限公司 | 一种抗凝逆转剂及其制备方法和应用 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE793059A (fr) | 1972-02-28 | 1973-04-16 | Ritzerfeld Gerhard | Dispositif d'encrage pour presses rotatives a |
JPS5632477B2 (instruction) | 1973-03-07 | 1981-07-28 | ||
DE2330742C2 (de) | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
JPS5610188B2 (instruction) | 1973-09-14 | 1981-03-06 | ||
JPS5756481B2 (instruction) | 1974-06-13 | 1982-11-30 | ||
CA1037234A (en) | 1976-06-01 | 1978-08-29 | Aluma Building Systems Incorporated | Wall forming structure for poured concrete walls |
FR2376188A1 (fr) | 1976-12-28 | 1978-07-28 | Elf Union | Procede de preparation de compositions de bitumes polymeres |
JPS54120627A (en) | 1978-03-13 | 1979-09-19 | Nittetsu Kakoki Kk | Regenaration of asphalt concrete |
JPS5576876A (en) | 1978-12-05 | 1980-06-10 | Grelan Pharmaceut Co Ltd | Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne |
JPS5581055A (en) | 1978-12-12 | 1980-06-18 | Kubota Ltd | Drawing device of pipe |
JPS55122779A (en) | 1979-03-13 | 1980-09-20 | Maruko Seiyaku Kk | Preparation of theobromine derivative |
CS201558B1 (en) | 1979-05-14 | 1980-11-28 | Pavol Kovar | Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine |
JPS5677279A (en) | 1979-11-28 | 1981-06-25 | Ota Seiyaku Kk | Preparation of xanthine derivative |
JPS56125451A (en) | 1980-03-08 | 1981-10-01 | Mitsubishi Gas Chem Co Inc | Production of modified asphalt |
JPS5762278A (en) | 1980-10-01 | 1982-04-15 | Sagami Chem Res Center | Theobromine derivative and its preparation |
JPS5780385A (en) | 1980-11-05 | 1982-05-19 | Mitsubishi Petrochem Co Ltd | Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine |
JPS5785387A (en) | 1980-11-14 | 1982-05-28 | Teikoku Chem Ind Corp Ltd | Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine |
JPS5798284A (en) | 1980-12-10 | 1982-06-18 | Kawashima Yakuhin Kaihatsu Kk | Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine |
JPS5838284B2 (ja) | 1981-04-14 | 1983-08-22 | ミサワホ−ム株式会社 | 脱型装置 |
JPS57200391A (en) | 1981-06-02 | 1982-12-08 | Daito Koeki Kk | 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine |
JPS58134092A (ja) | 1982-02-05 | 1983-08-10 | Sagami Chem Res Center | テオブロミン誘導体 |
JPS58150594A (ja) | 1982-03-03 | 1983-09-07 | Daito Koeki Kk | キサンチン誘導体の製造方法 |
CS237719B1 (cs) | 1983-05-12 | 1985-10-16 | Jan Jendrichovsky | SpAsob přípravy dimetyl-(5-oxohexyl)-xantlnov |
DE3508097A1 (de) | 1984-07-21 | 1986-02-06 | Hoechst Ag, 6230 Frankfurt | Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung |
DD274334A3 (de) | 1985-12-17 | 1989-12-20 | Dresden Arzneimittel | Verfahren zur herstellung von reinem 3,7-dimethyl-1-(5-oxohexyl)-xanthin |
IL106854A (en) | 1986-12-31 | 1996-05-14 | Hoechst Roussel Pharma | Pantoxifilin metabolites and pharmaceutical preparations containing them to prevent an immune reaction and to reduce undesirable conditions in this regard |
CS263595B1 (en) | 1988-01-06 | 1989-04-14 | Rybar Alfonz | Process for preparing 7-n-propyl-3-methyl-3,7-dihydro-1h-purin-2,6-dione |
JP2661666B2 (ja) | 1988-02-19 | 1997-10-08 | ヘキスト薬品工業株式会社 | 抗消化性潰瘍剤 |
IT1231779B (it) | 1989-08-09 | 1991-12-21 | Eniricerche Spa | Procedimento per l'ossidazione di composti paraffinici. |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
DE3942872A1 (de) | 1989-12-23 | 1991-06-27 | Hoechst Ag | Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen |
US5112827A (en) * | 1990-05-18 | 1992-05-12 | Board Of Regents, The University Of Texas System | Drug to reverse fatty liver and atheromatous lesions |
AU9084991A (en) | 1990-11-01 | 1992-05-26 | Board Of Regents, The University Of Texas System | Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues |
EP0484785B1 (en) | 1990-11-07 | 1996-05-22 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses |
EP0490181A1 (en) | 1990-11-30 | 1992-06-17 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for preparation of a medicament having immunosuppressing activity |
EP0493682A3 (en) | 1990-11-30 | 1992-11-19 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans |
US5763446A (en) | 1992-03-26 | 1998-06-09 | University Of Southern California | Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases |
US5804584A (en) * | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
HUT68560A (en) | 1993-08-02 | 1995-04-27 | Chinoin Gyogyszer Es Vegyeszet | The use of xantine derivatives for promotion of healing of operative lesions |
ATE372966T1 (de) * | 1994-03-25 | 2007-09-15 | Isotechnika Inc | Verbesserung der effektivität von arzneimitteln duren deuterierung |
EP0759915B1 (en) | 1994-05-16 | 2002-10-16 | Cell Therapeutics, Inc. | Asymmetric synthesis of chiral secondary alcohols |
DE4430128A1 (de) | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
AU3539795A (en) | 1994-08-25 | 1996-03-14 | Medical University Of South Carolina | Methods of treating cold symptoms using pentoxifylline |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
DE19544768C1 (de) | 1995-11-30 | 1997-07-10 | Rentschler Arzneimittel | Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
US5985592A (en) | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
US6248889B1 (en) | 1998-11-20 | 2001-06-19 | 3M Innovative Properties Company | Process for converting an alcohol to the corresponding fluoride |
US6417208B1 (en) | 1999-02-05 | 2002-07-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of identification of inhibitors of PDE1C |
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
GB0102107D0 (en) | 2001-01-26 | 2001-03-14 | Syngenta Ltd | Chemical process |
RS83503A (en) | 2001-05-03 | 2006-10-27 | F. Hoffmann-La Roche Ag. | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
WO2003013568A1 (en) | 2001-08-02 | 2003-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Cytokine modulation therapy |
JP2005508978A (ja) | 2001-11-02 | 2005-04-07 | ファイザー・プロダクツ・インク | Pde9阻害薬によるインスリン抵抗性症候群及び2型糖尿病の治療 |
EP1496940A2 (en) | 2002-03-14 | 2005-01-19 | Bayer Pharmaceuticals Corporation | Methods of treating diabetes using pde 11a inhibitors |
DE10214228A1 (de) | 2002-03-22 | 2003-10-02 | Bdd Group Holding Ag Zug | Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel |
US20050107420A1 (en) * | 2002-05-23 | 2005-05-19 | Boehringe Ingelheim Pharma Gmbh & Co. Kg | Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
EA012110B1 (ru) | 2003-06-30 | 2009-08-28 | Алтана Фарма Аг | Пирролодигидроизохинолины как ингибиторы pde10 |
JP2007508241A (ja) | 2003-07-31 | 2007-04-05 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Pde10a阻害剤を用いる糖尿病および関連障害の処置方法 |
WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
US20090162286A1 (en) | 2004-06-07 | 2009-06-25 | Pfizer Inc. | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions |
WO2006035417A2 (en) | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Dihydropyrimidine microcapsule - formulations |
BRPI0516170A (pt) | 2004-09-29 | 2008-08-26 | Cordis Corp | formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina |
BRPI0617987A2 (pt) | 2005-10-06 | 2011-08-16 | Auspex Pharmaceuticals Inc | composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico |
BRPI0908107A2 (pt) * | 2008-02-29 | 2019-09-24 | Concert Pharmaceuticals Inc | composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente |
-
2010
- 2010-09-01 US US12/873,991 patent/US20110053961A1/en not_active Abandoned
- 2010-09-02 CN CN201410746544.2A patent/CN104478881A/zh active Pending
- 2010-09-02 DK DK10814504.6T patent/DK2473053T3/en active
- 2010-09-02 CA CA2771123A patent/CA2771123C/en active Active
- 2010-09-02 PL PL10814504T patent/PL2473053T3/pl unknown
- 2010-09-02 PH PH1/2012/500278A patent/PH12012500278A1/en unknown
- 2010-09-02 JP JP2012528054A patent/JP5292516B2/ja active Active
- 2010-09-02 PT PT108145046T patent/PT2473053E/pt unknown
- 2010-09-02 ES ES10814504.6T patent/ES2542401T3/es active Active
- 2010-09-02 AU AU2010289465A patent/AU2010289465B2/en active Active
- 2010-09-02 ME MEP-2015-108A patent/ME02177B/me unknown
- 2010-09-02 HU HUE10814504A patent/HUE026800T2/en unknown
- 2010-09-02 BR BR112012008108A patent/BR112012008108B1/pt active IP Right Grant
- 2010-09-02 HR HRP20150797TT patent/HRP20150797T1/hr unknown
- 2010-09-02 SI SI201030985T patent/SI2473053T1/sl unknown
- 2010-09-02 EP EP15163741.0A patent/EP2963040A1/en not_active Withdrawn
- 2010-09-02 EA EA201270339A patent/EA023809B1/ru not_active IP Right Cessation
- 2010-09-02 EP EP20100814504 patent/EP2473053B1/en active Active
- 2010-09-02 CN CN201080039090.5A patent/CN102480968B/zh active Active
- 2010-09-02 IN IN1641DEN2012 patent/IN2012DN01641A/en unknown
- 2010-09-02 MX MX2012002705A patent/MX2012002705A/es active IP Right Grant
- 2010-09-02 WO PCT/US2010/047708 patent/WO2011028922A1/en active Application Filing
- 2010-09-02 KR KR1020127008446A patent/KR101591137B1/ko active Active
-
2012
- 2012-02-21 ZA ZA2012/01295A patent/ZA201201295B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN102480968B (zh) | 2015-01-07 |
HUE026800T2 (en) | 2016-07-28 |
EP2473053A4 (en) | 2013-03-27 |
AU2010289465B2 (en) | 2016-03-10 |
JP2013503894A (ja) | 2013-02-04 |
WO2011028922A1 (en) | 2011-03-10 |
EP2963040A1 (en) | 2016-01-06 |
CA2771123A1 (en) | 2011-03-10 |
BR112012008108B1 (pt) | 2019-10-22 |
KR101591137B1 (ko) | 2016-02-02 |
PL2473053T3 (pl) | 2015-10-30 |
EA201270339A1 (ru) | 2012-09-28 |
PH12012500278A1 (en) | 2012-10-22 |
BR112012008108A2 (pt) | 2015-09-22 |
EA023809B1 (ru) | 2016-07-29 |
ES2542401T3 (es) | 2015-08-05 |
CA2771123C (en) | 2017-11-14 |
KR20120050509A (ko) | 2012-05-18 |
CN104478881A (zh) | 2015-04-01 |
ME02177B (me) | 2015-10-20 |
EP2473053A1 (en) | 2012-07-11 |
JP5292516B2 (ja) | 2013-09-18 |
HRP20150797T1 (hr) | 2015-09-11 |
CN102480968A (zh) | 2012-05-30 |
HK1170377A1 (en) | 2013-03-01 |
AU2010289465A1 (en) | 2012-03-01 |
US20110053961A1 (en) | 2011-03-03 |
EP2473053B1 (en) | 2015-04-22 |
MX2012002705A (es) | 2012-04-02 |
ZA201201295B (en) | 2012-10-31 |
PT2473053E (pt) | 2015-09-14 |
SI2473053T1 (sl) | 2015-10-30 |
DK2473053T3 (en) | 2015-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12012500278A1 (en) | Substituted xanthine derivatives | |
WO2009108383A3 (en) | Substituted xanthine derivatives | |
IN2012DN01642A (instruction) | ||
CA2871471C (en) | Dna-pk inhibitors | |
MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
MX2009009590A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. | |
IL200793A0 (en) | Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases | |
MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
MX2009010037A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
MD4820B1 (ro) | Compuşi dihidroizochinolinonici substituiţi | |
MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
UA110197C2 (ru) | Соединения, эффективные как ингибиторы для ксантиноксидазы, процесса получения таких соединений и фармацевтической композиции, содержащей терапевтически эффективное количество таких соединений. | |
MX350761B (es) | Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa. | |
MX2009009592A (es) | Aminopiridinas utiles como inhibidores de proteinas cinasas. | |
TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
MX2009011811A (es) | Aminopirimidinas utiles como inhibidores de cinasa. | |
MX2009000169A (es) | Derivados de purinona como agonistas de hm74a. | |
MX337849B (es) | Composiciones y metodos para inhibicion de la via jak. | |
JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
NZ727188A (en) | Aldosterone synthase inhibitors | |
MX2011008645A (es) | Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa. | |
WO2013155465A8 (en) | Substituted xanthine derivatives | |
MX2011012524A (es) | Inhibidores de proteina cinasa c-met. |